Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... Hand Hygiene Day is May 5 and UMF Corporation ... staff that without environmental hygiene as a component, hand-washing ... (HAIs). "Studies show that hand-hygiene compliance is ... were possible to achieve 100 percent compliance, hand hygiene ...
...  BONESUPPORT, an emerging leader in injectable bone substitutes for ... orthopedic surgery, announced today that it has been selected ... Herring,s 2012 Europe Award, a prestigious list honoring the ... business region.  BONESUPPORT was one of only nine winners ...
Cached Medicine Technology:Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation 2BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award 2BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award 3
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... sales in the first half of Craneware,s 10th Anniversary YearATLANTA, Feb. ... improvement software for hospitals and health systems, is pleased to announce ... Highlights , , ... (H108: $12.9m) contributing to: , ...
... Hall to be Board Chairman; Siegrist Takes on Executive PostSOUTH ... announced his decision to transition from president and chief executive ... Inc., effective March 16. Rick Siegrist, M.B.A., president of a ... member of the Press Ganey Board of Directors, will take ...
... U.S. Department of Labor,s Occupational Safety and Health Administration ... Co., doing business as Ro-Corp Inc., for alleged willful, ... proposing more than $1.2 million in penalties for numerous ... the company,s facility in East St. Louis.OSHA began an ...
... The following was released today by SEIU UHW: NOTE TO ... expected to reach Congress--several hundred SEIU members from around the ... president,s vision to fix healthcare. The rally will be held at ... noon. California Healthcare for America Now (HCAN) ...
... disease severity, experts say, , , WEDNESDAY, Feb. 25 ... gene associated with cystic fibrosis. , Dr. Christopher ... and an international team of colleagues demonstrated that ... the airway disease that marks cystic fibrosis (CF) ...
... A newly released joint guideline produced by the American ... Association (AUA) recommends that healthy men who are screened ... the disease should talk to their doctors about using ... 5-ARIs lower the level of the hormone dihydrotestosterone (DHT), ...
Cached Medicine News:Health News:Craneware Announces Half-Year Results 2Health News:Changing of the Guard at Press Ganey 2Health News:Changing of the Guard at Press Ganey 3Health News:U.S. Department of Labor's OSHA proposes more than $1.2 million penalty to St. Louis area chemical repackaging and distribution company 2Health News:L.A. Area SEIU Members Gear Up to Support Effort to Fix Healthcare; Plan Rally for Thursday 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 3Health News:New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk 2
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Medicine Products: